Determination of avidity of IgG against protein antigens from *Streptococcus pneumoniae*: assay development and preliminary application in clinical settings

D. C. Andrade 1 · I. C. Borges 1 · N. Ekström 2 · T. Jartti 3 · T. Puhakka 4,5 · A. Barral 6 · H. Kayhty 2 · O. Ruuskanen 3 · C. M. Nascimento-Carvalho 7

Received: 20 June 2017 / Accepted: 4 September 2017
© Springer-Verlag GmbH Germany 2017

Abstract The measurement of antibody levels is a common test for the diagnosis of *Streptococcus pneumoniae* infection in research. However, the quality of antibody response, reflected by avidity, has not been adequately evaluated. We aimed to evaluate the role of avidity of IgG against eight pneumococcal proteins in etiologic diagnosis. Eight pneumococcal proteins (Ply, CbpA, PspA1 and 2, PcpA, PhtD, StkP-C, and PcsB-N) were used to develop a multiplex bead-based avidity immunoassay. The assay was tested for effects of the chaotropic agent, multiplexing, and repeatability. The developed assay was applied to paired samples from children with or without pneumococcal disease (n = 38 for each group), determined by either serology, polymerase chain reaction (PCR), or blood culture. We found a good correlation between singleplex and multiplex assays, with r ≥ 0.94. The assay was reproducible, with mean inter-assay variation ≤ 9% and intra-assay variation < 6%. Children with pneumococcal disease had lower median avidity indexes in the acute phase of disease for PspA1 and 2 (p = 0.042), PcpA (p = 0.002), PhtD (p = 0.014), and StkP-C (p < 0.001). When the use of IgG avidity as a diagnostic tool for pneumococcal infection was evaluated, the highest discriminative power was found for StkP-C, followed by PcpA (area under the curve [95% confidence interval, CI]: 0.868 [0.759–0.977] and 0.743 [0.607–0.879], respectively). The developed assay was robust and had no deleterious influence from multiplexing. Children with pneumococcal disease had lower median avidity against five pneumococcal proteins in the acute phase of disease compared to children without disease.

Introduction

*Streptococcus pneumoniae* is an important cause of morbidity and mortality in children worldwide [1]. The evaluation of the antibody response against capsular polysaccharides of this bacterium has been largely used as a tool for diagnostic purposes and to evaluate response to pneumococcal vaccines [2–4]. Over the past several decades, however, several new protein antigens from *S. pneumoniae* have been identified and recognized as specific and conserved antigens [5–7], suitable for use in diagnostic assays and experimental vaccines. Promising antigens include proteins involved in the pathogenesis of pneumococcal infections and which interact in many ways with the host immune system, such as pneumolysin (Ply), choline binding protein A (CbpA), pneumococcal surface protein A (PspA), pneumococcal choline binding protein A (PcpA), pneumococcal histidine triad protein D (PhtD),
serine/threonine protein kinase (StkP), and protein required for cell wall separation of group B streptococcus (PcsB). Ply is a highly conserved cytotoxin released during autolysis [6, 7]; CbpA and PspA are choline binding proteins which share molecular similarities [6–10]; PcpA and PhtD are surface proteins which function as adhesins [11–13]; and StkP and PcsB are immunogenic proteins recently discovered, which are supposed to play roles in cell division and peptidoglycan metabolism, respectively [14–16]. Indeed, new vaccine formulations using the aforementioned pneumococcal proteins are being tested in both human and animal trials [17–19], and serological assays using these antigens are being developed and validated [20–22].

The antibody response against pneumococcal antigens is usually evaluated through the measurement of antigen-specific antibody levels. However, samples collected at different time points are required when the quantitation of antibodies is used for diagnostic purposes, representing a limitation of this method in the clinical setting. Therefore, assays able to evaluate the effectiveness of an antibody response using only one serum sample are warranted. The functionality of antibodies against a specific antigen reflects the quality of the immune response, and may be evaluated through antibody avidity assays [2]. Avidity represents the strength of antigen–antibody binding, and has been used as a diagnostic tool for viral infections [23, 24]. Furthermore, it has been reported to increase following exposure to S. pneumoniae [2, 25]. To date, the avidity of IgG antibodies against pneumococcal proteins has only been evaluated in a few studies, mostly experimental vaccine trials [17, 18]. The objectives of this study were to validate a multiplex avidity assay using eight pneumococcal protein antigens, and to apply the developed assay to a clinical setting composed of children with and without pneumococcal disease with samples collected at admission and during convalescence.

Materials and methods

Reagents

A multiplexed avidity assay was designed using eight distinct recombinant pneumococcal protein antigens: Ply, CbpA, PspA family 1 (PspA1), PspA family 2 (PspA2), PcpA, PhtD, StkP-C (a C-terminal fragment of StkP), and PcsB-N (an N-terminal fragment of PcsB). A truncated PcpA [26] and PhtD [27] were supplied by Sanofi Pasteur (Sanofi Pasteur S.A., Marcy-L’Etoile, France); Ply [28], CbpA [29], and PspA1 (UAB055) [8] were supplied by Prof. Elaine Tuomanen at St. Jude’s Children’s Research Hospital (Memphis, TN, USA); PspA 2 was supplied by Pat Coan and Prof. Susan Hollingshead and David Briles at the University of Alabama (Birmingham, AL, USA); and StkP-C and PcsB-N were supplied by Valneva Austria GmbH (Vienna, Austria) [14]. Protein antigens included in this assay were chosen based on previous data on immunogenicity profiles [6–14] and natural development of antibodies [30].

Hydroxysulfosuccinimide (Sulfo-NHS) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) were obtained from Thermo Fisher Scientific, Rockford, IL, USA. R-phycocerythrin (R-PE)-conjugated AffiniPure Goat Anti-Human IgG Fcγ Fragment Specific was purchased from Jackson ImmunoResearch Laboratories, Inc. (Westgrove, PA, USA). Sodium thiocyanate 98% was obtained from Sigma-Aldrich (St. Louis, MO, USA). Carboxylated MicroPlex beads were obtained from Luminex Corporation (Austin, TX, USA). Fetal bovine serum was obtained from Life Technologies (Paisley, UK).

Serum samples

Patient sera that had been sent to the National Institute for Health and Welfare (Helsinki, Finland) for antibody testing were used without identification for optimization of the avidity assay, evaluation of the effect of Sodium thiocyanate on the antigen-conjugated beads, and to assess the optimal range of fluorescence readings for the determination of avidity indexes. Thirteen paired samples from Brazilian children with invasive pneumococcal disease (IPD) determined by either blood culture (9 cases) or blood polymerase chain reaction (PCR) using the ply primer (4 cases) were used as pneumococcal patients [20]. Paired samples from 13 healthy Finnish children who were submitted to elective tonsillectomy were used as non-pneumococcal patients [20]. Finally, the developed avidity assay was used to test paired samples from 50 children with non-bacteremic community-acquired pneumonia (CAP), which were selected based on the adequacy of the fluorescence readings for avidity testing. Out of these 50 patients, 25 had increases in anti-protein-specific IgG between acute and convalescent samples and 25 failed to respond to any of the studied pneumococcal antigens. The presence of serological response was defined as a ≥ 2-fold increase in the antibody levels for IgG against Ply, CbpA, PspA1 and 2, PhtD, StkP-C, or PcsB-N, or a ≥ 1.5-fold increase in the antibody levels for IgG against PcpA [20]. The flow chart for the patients whose samples were tested in this study is shown in Fig. 1. All the samples evaluated for avidity were from patients aged 1 to 57 months, out of which 5 patients were less than 6 months of age.

The use of the samples was approved by the Ethics Committee of the Federal University of Bahia in Brazil, the Ethics Committee of the National Institute for Health and Welfare in Finland (formerly National Public Health Institute), and the Ethics Committee of Satakunta Central Hospital, Pori, Finland.
**Coupling of proteins to the beads and serologic assay**

A multiplexed bead-based serologic assay using Luminex xMAP® Technology to determine the levels of anti-protein-specific IgG was performed as previously described [21]. Pneumococcal proteins were coupled to activated carboxylated MicroPlex beads by a two-step carbodiimide reaction [20, 21]. Each pneumococcal protein was conjugated in one bead set, except for PspA1 and 2, which were conjugated mixed on the same bead set. Samples were analyzed using a Luminex 200 device and software (xMAP® Technology, Luminex Corporation, Austin, TX, USA).

**Avidity assay**

Initially, 25 μL of the F-PBS diluted serum sample in 12 replicates and 25 μL of beads diluted in F-PBS were transferred to each well of a 96-well plate (Millipore MSHVNA510, Merck KGaA, Darmstadt, Germany). Samples were diluted from 1:100 up to 1:6400, aiming to create fluorescence readings on the optimal range for the avidity assay. The plate was then incubated on a shaker at 900 rpm for 1 min and 600 rpm for 60 min at room temperature. The plate was then washed as above and 80 μL/well of PBS was added. True duplicates were used throughout the development of this protocol and the median fluorescence intensity (MFI) values were averaged. The avidity index was calculated as the molar concentration of Sodium thiocyanate required to elute 50% of the bound specific antibody in a given sample [2, 3, 31].

**Determination of the effect of Sodium thiocyanate on conjugated beads**

Beads conjugated with each of the studied antigens were tested for the effect of a 6 M solution of Sodium thiocyanate in PBS to ensure that Sodium thiocyanate does not disrupt the antigenic structures of the antigens. A quantity of 25 μL of bead solution was incubated with either 25 μL of a 6 M Sodium thiocyanate solution or PBS for 15 min at 600 rpm in the dark. After incubation, the plate was washed twice with a vacuum washer and serial 1:4 dilutions of a serum sample with high levels of IgG against the evaluated antigens was added and the assay proceeded as described previously [21].

**Determination of the optimal range of fluorescence for avidity testing**

Samples with a distinct range of MFI for all the studied antigens were assayed for avidity as previously described. Seven serial 1:4 dilutions from two serum samples were assayed for avidity. The avidity index for each sample dilution was calculated and the range of MFI that yielded consistent avidity indexes was determined.
Comparison of singleplex and multiplex assays

The comparability between the single- and multiplex avidity assays was evaluated by determining the avidity index for a sample with high values of anti-protein IgG for all studied antigens by both formats.

Repeatability

Repeatability of the avidity assay was assessed by determining both intra- and inter-assay variation for each antigen. Intra-assay variation was calculated from eight repetitions of one sample in the same plate. Inter-assay variation was calculated from the results of two repetitions of eight samples of Brazilian children with CAP on different days. The percentage coefficient of variation (CV) was calculated for each of these results and averaged.

Evaluation of avidity in clinical settings

The avidity of IgG against pneumococcal proteins was evaluated in paired serum samples from 13 children with IPD (positive cases), 13 healthy children (negative cases), and 50 children with non-invasive CAP (25 with and 25 without serological response against S. pneumoniae). The avidity indexes were compared based on the group of analysis and time of sample collection (acute or convalescent samples, collected 2–4 weeks apart).

Statistical analysis

Categorical variables were presented as absolute number (percentage) and continuous variables as median (25th–75th percentiles), as they showed non-parametric distributions. Categorical variables were compared using the Chi-square or Fisher’s exact test as appropriate, and continuous variables were evaluated using the Mann–Whitney U-test. Comparison between samples collected at different time points was performed using the Wilcoxon signed-rank test. Receiver operating characteristic (ROC) curves were plotted to determine the accuracy of avidity of IgG against pneumococcal proteins in differentiating children with or without pneumococcal disease, using either each antigen individually or combinations of different antigens. All statistical tests were two-tailed (significance level of 0.05) using SPSS software (version 9.0).

Results

Optimization of the avidity assay

Determination of the effect of Sodium thiocyanate on conjugated beads

The comparison between beads pretreated with 6 M solution of Sodium thiocyanate or PBS is shown in Fig. 2. Overall, the chaotropic agent did not have an effect on the antigens that would inhibit the binding of IgG to most conjugated beads, and similar fluorescence readings were obtained with or without treatment with Sodium thiocyanate. A decrease in the fluorescence readings was found solely for beads conjugated with PcpA. Nevertheless, we still found a good correlation between fluorescence readings obtained with or without treatment with Sodium thiocyanate for all the studied antigens, with a corresponding correlation coefficient ≥ 0.97 for all of them. Also, no difference was found when the fluorescence readings from pretreated beads with 6 M solution of Sodium thiocyanate or PBS were compared (data not shown). There was no effect from the thiocyanate treatment on background MFI levels (data not shown).
Determination of the optimal range of fluorescence for avidity testing

The developed avidity assay gave consistent results in the MFI range from 100 up to 7000, with the coefficient of variation ranging from 1% for Ply up to 12% for PspA. Higher values presented greater variability in the avidity index, and lower values were often out of the linear range of the serologic assay [21]. Values outside the determined linear range were excluded from the analysis. The number of samples included in the avidity analysis is shown in Table 1.

Comparison of singleplex and multiplex assays

We found good correlation between avidity indexes determined by the singleplex and multiplex assays, with a correlation coefficient $\geq$ 0.94 for all the studied antigens, as shown in Fig. 3. Therefore, multiplexing did not have an effect on the results of the developed avidity assay.

Repeatability

The developed avidity assay had good robustness regarding inter- and intra-assay variation. The intra-assay variation ranged from 0% for PepA up to 6% for Ply, and the inter-assay variation ranged from 2% for CbpA up to 9% for PspA1 and 2 (data not shown).

Determination of IgG avidity in clinical settings

This study included 76 children whose median age was 19 months ([25th–75th percentile]: 12–32 months) and the median interval of serum sample collection was 21 days.
Children with pneumococcal disease diagnosed by either serology, blood culture, or blood PCR had samples collected within a shorter time interval (median [25th–75th percentile]: 20 [17–25] vs. 23 [18–41] days; \( p = 0.011 \)) when compared to the group of children without pneumococcal disease (including healthy children and children with CAP without serological response to \( S. \) pneumoniae), but there was no statistical difference in age (median [25th–75th percentile]: 16 [10–28] vs. 24 [14–39] months; \( p = 0.054 \)). When evaluating solely the group of children without pneumococcal disease, children with CAP without serological response to \( S. \) pneumoniae were younger (median [25th–75th percentile]: 16 [10–28] vs. 24 [14–39] months; \( p = 0.054 \)) and had samples collected at a shorter time interval (median [25th–75th percentile]: 19 [17–23] vs. 44 [40–52] days; \( p < 0.001 \)) when compared to the subgroup of healthy children submitted to elective tonsillectomy (negative cases). There was no difference in age and sampling interval between children with IPD and children with CAP and serological response against \( S. \) pneumoniae (data not shown).

Initially, we compared the IgG avidity elicited in children with IPD and healthy children submitted to elective tonsillectomy, as shown in Table 2. In children with IPD, lower median IgG avidity than in healthy children was found in the acute phase for PcpA, PhtD, and PcsB-N. In the convalescent phase, Table 2: Comparison of the avidity index obtained from children with invasive pneumococcal disease (positive cases) and healthy children submitted to elective tonsillectomy (negative cases), on the acute and convalescent serum samples

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Acute serum sample</th>
<th>Convalescent serum sample</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Invasive pneumococcal disease ((n = 13))</td>
<td>Healthy children ((n = 13))</td>
</tr>
<tr>
<td>Ply</td>
<td>4.6 (2.7–5.8)</td>
<td>4 (3.8–4.8)</td>
</tr>
<tr>
<td>CbpA</td>
<td>2.4 (1.9–2.7)</td>
<td>2.8 (2.5–3)</td>
</tr>
<tr>
<td>PspA1 and 2</td>
<td>0.8 (0.4–1.3)</td>
<td>1.2 (0.8–1.5)</td>
</tr>
<tr>
<td>PcpA</td>
<td>1.3 (0.4–1.4)</td>
<td>1.5 (1.4–2)</td>
</tr>
<tr>
<td>PhtD</td>
<td>2.2 (1.9–3.6)</td>
<td>4.2 (3.4–4.4)</td>
</tr>
<tr>
<td>StkP-Cb</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>PcsB-N</td>
<td>1.8 (1.1–2.4)</td>
<td>3 (2.2–3.4)</td>
</tr>
</tbody>
</table>

\(^a\)Invasive pneumococcal disease: 9 patients with positive blood culture and 4 patients with positive blood PCR

\(^b\)Data from the first serum sample from the group with invasive pneumococcal disease was not considered for the analysis due to insufficient sampling

\(^c\)Number of included samples: 25

\(^d\)Number of included samples: 21

\(^e\)Number of included samples: 21

\(^f\)Number of included samples: 18

\(^g\)Number of included samples: 24

\(^h\)Number of included samples: 24

\(^i\)Number of included samples: 24

\(^j\)Number of included samples: 24

\(^k\)Number of included samples: 24

\(^l\)Number of included samples: 20

\(^m\)Number of included samples: 24

\(^n\)Number of included samples: 8

\(^o\)Number of included samples: 22
lower IgG avidity in the group with IPD than in healthy children was found for PhtD and PcsB-N.

Subsequently, we compared the IgG avidity indexes within the groups of children with and without pneumococcal disease. We found no difference in either acute or convalescent samples between children with pneumococcal disease diagnosed by blood PCR and blood culture or serology, as shown in Table 3. On the comparison of healthy children submitted to elective tonsillectomy and children with CAP without serological response to *S. pneumoniae*, we found that children with pneumonia had a lower median IgG avidity index against PhtD in both acute and convalescent samples. These results are shown in Table 4.

When evaluating the IgG avidity indexes from children with pneumococcal disease diagnosed by either serology, culture, or PCR and children without pneumococcal disease (including healthy children and children with CAP without serological response to *S. pneumoniae*), we found that children with pneumococcal disease had lower median IgG avidity indexes in both acute and convalescent samples, as shown in Table 5. The IgG avidity indexes for PspA1 and 2, PcpA, PhtD, and StkP-C were significantly lower in the acute sample for the group with pneumococcal disease. On the convalescent phase, significantly lower IgG avidity was found for CbpA, PspA1 and 2, PhtD, StkP-C, and PcsB-N.

There was no difference in the median IgG avidity index between acute and convalescent samples in children with and without pneumococcal disease (data not shown). A modest increase in IgG avidity between acute and convalescent samples was found among children with pneumococcal disease for PcpA (1.4 [0.9–1.8] vs. 1.5 [0.8–1.7]; *p* = 0.250), StkP-C (2.5 [1.3–3] vs. 3.1 [1–3.4]; *p* = 0.236), and PcsB-N (2.30 [1.6–3.1] vs. 2.35 [1.6–3.3]; *p* = 0.204).

**Evaluation of diagnostic applications for IgG avidity**

The ROC curves for PspA1 and 2, PcpA, PhtD, and StkP-C are shown in Fig. 4, as well as the number of values included in the analysis, and the accuracy, specificity, and sensitivity of the cut-offs for each antigen. The optimal cut-off points were chosen based on the highest accuracy for each antigen.

---

**Table 3** Comparison of the avidity indexes between children with pneumococcal disease diagnosed by either blood PCR and blood culture (invasive pneumococcal disease) or serology

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Acute serum sample</th>
<th>Convalescent serum sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ply</td>
<td>4.6 (2.7–5.8)</td>
<td>4.2 (3.6–5.2)</td>
</tr>
<tr>
<td>CbpA</td>
<td>2.4 (1.9–2.7)</td>
<td>2.6 (2.2–2.9)</td>
</tr>
<tr>
<td>PspA1 and 2</td>
<td>0.8 (0.4–1.3)</td>
<td>1.2 (0.6–1.9)</td>
</tr>
<tr>
<td>PcpA</td>
<td>1.3 (0.4–1.4)</td>
<td>1.1 (0.6–1.7)</td>
</tr>
<tr>
<td>PhtD</td>
<td>2.2 (1.9–3.6)</td>
<td>3 (2.4–3.8)</td>
</tr>
<tr>
<td>StkP-C^b^</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>PcsB-N</td>
<td>1.8 (1.1–2.4)</td>
<td>2.5 (1.7–3.1)</td>
</tr>
</tbody>
</table>

^a^ Invasive pneumococcal disease: 9 patients with positive blood culture and 4 patients with positive blood PCR

^b^ Data from the first serum sample from the group with invasive pneumococcal disease was not considered for the analysis due to insufficient sampling

^c^ Number of included samples: 38

^d^ Number of included samples: 29

^e^ Number of included samples: 33

^f^ Number of included samples: 24

^g^ Number of included samples: 33

^h^ Number of included samples: 35

^i^ Number of included samples: 37

^j^ Number of included samples: 31

^k^ Number of included samples: 32

^l^ Number of included samples: 17

^m^ Number of included samples: 33

^n^ Number of included samples: 11

^o^ Number of included samples: 34
The highest discriminative power was found for StkP-C, followed by PcpA. The area under the curve varied from 0.65 up to 0.85, and the optimal cut-offs of avidity for the diagnosis of pneumococcal disease were: < 0.9 for PspA1 and 2, < 1.2 for PcpA, < 3.1 for Ph5D, and < 2.8 for StkP-C. Similar results were obtained when the ROC curves were plotted considering children with pneumococcal disease diagnosed by either serology, blood culture, or PCR as positive cases and solely the group of children with CAP without serological response against \textit{S. pneumoniae} as negative cases (data not shown).

Finally, there was an increase in the accuracy of IgG avidity for the diagnosis of pneumococcal disease by combining the avidity indexes against PcpA and StkP-C, as shown in Fig. 5, with an area under the curve of 0.871 (95% CI: 0.8–0.942). The comparison of the median difference between acute and convalescent samples for all antigens is shown in Fig. 6.

**Discussion**

In this report, we describe the development and validation of a multiplex avidity assay using pneumococcal proteins. When the assay was applied to a clinical setting, we found that children with pneumococcal infection present lower median avidity of IgG against protein antigens when compared to children without evidence of pneumococcal infection. Furthermore, data from the ROC curve analysis suggest that avidity studies might be useful as a diagnostic tool requiring serum sample collection only in the acute phase of disease.

The avidity of IgG against pneumococcal polysaccharides has been largely studied in vaccine trials, as a tool to evaluate the quality of the antibody response \cite{3, 32}. Avidity tests may be used as a measure of functionality of the antibody response, and a negative correlation between antibody avidity and the antibody concentration required for opsonophagocytic/bactericidal activity has been reported in previous studies \cite{33–35}. The use of avidity to evaluate antibody response against pneumococcal proteins, however, has only been used in a few studies, mostly experimental vaccine trials with animal models \cite{17, 18}. Therefore, in the current setting, where new vaccines using protein antigens are under development \cite{19}, the validation of cost-effective protocols to evaluate the avidity of IgG against protein antigens is warranted. Herein, we described the validation of a robust avidity assay, in which

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Acute serum sample</th>
<th>Convalescent serum sample</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Healthy children (n = 13)</td>
<td>Children without serological response (n = 25)</td>
</tr>
<tr>
<td>Ply</td>
<td>4 (3.8–4.8)</td>
<td>3.9 (3.4–4.8)</td>
</tr>
<tr>
<td>CbpA</td>
<td>2.8 (2.5–3)</td>
<td>2.7 (2.5–2.8)</td>
</tr>
<tr>
<td>PspA1 and 2</td>
<td>1.2 (0.8–1.5)</td>
<td>1.6 (1.1–2.4)</td>
</tr>
<tr>
<td>PcpA</td>
<td>1.5 (1.4–2)</td>
<td>1.6 (1.3–1.9)</td>
</tr>
<tr>
<td>Ph5D</td>
<td>4.2 (3.4–4.4)</td>
<td>3.2 (2.7–3.7)</td>
</tr>
<tr>
<td>StkP-C</td>
<td>3.2 (2.8–4.3)</td>
<td>3.5 (3.1–4.1)</td>
</tr>
<tr>
<td>PcsB-N</td>
<td>3 (2.2–3.4)</td>
<td>2.7 (2–3.1)</td>
</tr>
</tbody>
</table>

a Number of included samples: 37
b Number of included samples: 25
c Number of included samples: 32
d Number of included samples: 31
e Number of included samples: 33
f Number of included samples: 24
g Number of included samples: 34
h Number of included samples: 37
i Number of included samples: 26
j Number of included samples: 26
k Number of included samples: 30
l Number of included samples: 31
m Number of included samples: 25
n Number of included samples: 34
there was no deleterious effect from the multiplexing or from the use of a chaotropic agent on the conjugated beads. Nevertheless, the fluorescence intensity readings (which are proportional to the IgG antibody concentrations in the sample) in this avidity assay should remain within a predetermined interval (MFI between 100 and 7000) to ensure the consistency of the results. Furthermore, multiple dilutions of the same sample may be required since the antibody concentrations to different antigens in a sample may vary.

Herein, we found that children with pneumococcal disease present lower avidity of antibodies against most evaluated protein antigens in both acute and convalescent serum samples, compared to children without pneumococcal disease (Table 5). Similar results were found when comparing solely children with IPD with healthy controls (Table 2). To the best of our knowledge, the avidity of IgG against pneumococcal protein antigens in clinical settings has only once been evaluated previously, in a study testing the avidity of IgG against Ply, CbpA, and PspA in a group composed of 20 children with IPD and 20 healthy controls [25]. In that study, higher avidity was found in children with IPD in the convalescent phase of disease when compared to the control group. The results from previous studies evaluating the avidity of antibodies against capsular polysaccharides, however, have also found lower avidity in children with pneumococcal disease. For instance, children with recurrent respiratory infections presented lower avidity of IgG against capsular polysaccharides when compared to healthy controls, in a study evaluating the antibody levels against 12 pneumococcal serotypes [2]. Low avidity and opsonic activity have also been reported against the infecting serotype in children with IPD [4]. In this scenario, the presence of high-avidity antibodies against pneumococcal polysaccharides has been described as a protective factor against pneumococcal infection [33, 35, 36]. It is possible, therefore, that the higher avidity against pneumococcal proteins in the group of children without pneumococcal disease found herein may also be a determinant of protection against infection by this bacterium.

Herein, we did not find a statistically significant increase in IgG avidity between acute and convalescent serum samples. An increase in avidity against pneumococcal proteins has been reported by Ota et al. [25], who found lower avidity of IgG against Ply, CbpA, and PspA in the acute phase of disease in children with IPD compared to the convalescent phase of disease. Nevertheless, these differences did not reach statistical significance. It is possible that the small sample size from

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Acute serum sample</th>
<th>Convalescent serum sample</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pneumococcal disease (n = 38)</td>
<td>No pneumococcal disease (n = 38)</td>
<td></td>
</tr>
<tr>
<td>Ply</td>
<td>4.2 (3.3–5.5)</td>
<td>4 (3.5–4.8)</td>
<td>0.611&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>CbpA</td>
<td>2.6 (2.1–2.9)</td>
<td>2.7 (2.5–2.9)</td>
<td>0.150&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>PspA1 and 2</td>
<td>1 (0.5–1.7)</td>
<td>1.4 (0.9–2.1)</td>
<td>0.042&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>PcpA</td>
<td>1.2 (0.6–1.5)</td>
<td>1.5 (1.4–1.9)</td>
<td>0.002&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>PhfD</td>
<td>3 (1.9–3.7)</td>
<td>3.4 (2.9–4.1)</td>
<td>0.014&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>StkP-C</td>
<td>2.7 (1.4–3.1)</td>
<td>3.45 (3–4.1)</td>
<td>&lt;0.001&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td>PcsB-N</td>
<td>2.2 (1.5–3.1)</td>
<td>2.75 (2.1–3.1)</td>
<td>0.072&lt;sup&gt;g&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> Number of included samples: 75  
<sup>b</sup> Number of included samples: 54  
<sup>c</sup> Number of included samples: 65  
<sup>d</sup> Number of included samples: 55  
<sup>e</sup> Number of included samples: 66  
<sup>f</sup> Number of included samples: 40  
<sup>g</sup> Number of included samples: 69  
<sup>h</sup> Number of included samples: 74  
<sup>i</sup> Number of included samples: 57  
<sup>j</sup> Number of included samples: 63  
<sup>k</sup> Number of included samples: 47  
<sup>l</sup> Number of included samples: 69  
<sup>m</sup> Number of included samples: 36  
<sup>n</sup> Number of included samples: 68
both our study and that from Ota et al. have prevented the detection of statistically significant increases in avidity between acute and convalescent samples, which would represent the maturation of antigen-specific antibodies as a response to exposure to pneumococcal antigens.

On the evaluation of antibody avidity as a diagnostic tool for pneumococcal disease, we found that different proteins had varying discriminative powers for the detection of infection caused by \textit{S. pneumoniae}. Overall, antibodies to StkP-C and PcpA presented high accuracy and could be considered as a candidate for an avidity assay in clinical practice. Furthermore, the use of combinations of different antigens in avidity assays may increase the accuracy of the test for the diagnosis of pneumococcal disease in children, as we showed herein for a combined assay of PcpA and StkP-C. The use of avidity has the advantage of requiring only one serum sample to provide diagnostic information, compared to serological assays, which required paired samples. For instance, the avidity of IgG against pneumococcal polysaccharides was evaluated for diagnostic purposes by Fried et al. [2], who described a high discriminative power for avidity to distinguish between groups of children with recurrent bacterial infections.
respiratory infections and healthy controls. Nevertheless, the adequate validation of avidity protocols and definition of cut-off points for the diagnosis of acute disease is still required, particularly for assays including pneumococcal proteins that have only recently been described. Herein, we presented a preliminary evaluation of the optimal cut-offs of avidity for the diagnosis of pneumococcal disease and found a large range of avidity indexes when the cut-off points were chosen based on the highest accuracy for each protein. This finding reinforces the need for an individualized validation for each protein antigen.

The limitations of this study should be noted. Firstly, there were important differences within the group of children without pneumococcal disease (i.e., between the subgroup of healthy children and the subgroup of children with CAP without serological response to \textit{S. pneumoniae}), such as nationality, age, and sampling interval. However, when the avidity of IgG between the subgroups was evaluated, a difference between the subgroups was found only for PhtD. It is possible that the older age in the subgroup of healthy children may have contributed to the higher avidity found against PhtD due to the longer time of possible exposition to \textit{S. pneumoniae}. Secondly, a considerable amount of samples were excluded from the analysis due to the detection of antibody levels outside the determined optimal range. Unfortunately, repetitions could not be performed for such samples due to material and time restrictions. It is important to emphasize, however, that this was a preliminary study aiming to standardize and apply the first avidity assay in multiplex against eight pneumococcal antigens, and the described protocol should be re-evaluated using a larger panel of patient samples. Secondly, we included samples of five children aged under 6 months of age, who could still be, theoretically, under the protection of maternal antibodies. It is important to note, however, that antibody increases against pneumococcal proteins have already been reported in children aged under 6 months in the setting of symptomatic respiratory infections, such as CAP and acute otitis media [20, 37, 38]. Therefore, as young children can produce significant quantitative antibody responses despite the presence of maternal antibodies, we hypothesize that avidity should also be affected during pneumococcal infection. Thirdly, there was a decrease in the fluorescence readings for PcpA following treatment with 6 M Sodium thiocyanate. Nevertheless, we still found a high correlation between beads conjugated with this antigen which were pretreated with Sodium thiocyanate or not (Fig. 2). Finally, we had no data on colonization of the included children by \textit{S. pneumoniae}, and how this form of contact with the pneumococcus could affect the avidity of anti-protein IgG. It has been reported that children with social mixing with other children, a risk factor to pneumococcal colonization, had higher avidity of IgG against some pneumococcal serotypes than lone children [39]. The effect of colonization with \textit{S. pneumoniae} on the avidity of antibodies against pneumococcal proteins should be the focus of future studies.

In conclusion, this was the first report of the development and validation of an avidity assay in multiplex using pneumococcal proteins, which was robust and had no deleterious effect from multiplexing. When applied to a clinical setting, the described assay was able to identify differences in avidity of anti-protein IgG between groups of children with and without pneumococcal disease, with lower avidity found in the group of children with pneumococcal disease. The avidity of antibodies against pneumococcal proteins may also be used as a diagnostic tool for pneumococcal infection, and the protein antigens StkP-C and PcpA should be considered for inclusion in such an assay.

Acknowledgements We thank Sanofi Pasteur (Lyon, France) for supplying PcpA and PhtD; Prof. Elaine Tuomanen at St. Jude Children’s Research Hospital (Memphis, TN, USA) for supplying Ply, CbpA, and PspA1; Profs. Susan Hollingshead, David Briles, and Pat Coan at University of Alabama (Birmingham, AL, USA) for supplying PspA2; and Valneva Austria GmbH (Vienna, Austria) for supplying StkP-C and PcsB-N.
Data availability statement  The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding  This work was supported by: Bahia State Agency for Research Funding (FAPESB), Brazil; Brazilian Council for Scientific and Technological Development (CNPq), Brazil; Turku University Hospital Research Foundation, Finland; Rauno and Anne Puolimatka Foundation, Finland; Sohlberg Foundation, Finland.

Compliance with ethical standards

Conflict of interest  The authors declare that they have no conflict of interest.

Ethical approval  The use of the samples was approved by the Ethics Committee of the Federal University of Bahia in Brazil, the Ethics Committee of the National Institute for Health and Welfare in Finland (formerly National Public Health Institute), and the Ethics Committee of Satakunta Central Hospital, Pori, Finland.

Informed consent  Written informed consent was obtained from legal guardians before recruitment.

References


